NASDAQ:CERC Cerecor (CERC) Stock Price, News & Analysis → Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It! (From American Alternative) (Ad) Free CERC Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$12.33▼$13.7450-Day Range$2.06▼$3.2452-Week Range$1.98▼$4.50Volume73,477 shsAverage Volume1.27 million shsMarket Capitalization$1.25 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsInsider TradesSocial MediaStock AnalysisCompetitorsInsider TradesSocial Media Get Cerecor alerts: Email Address Ad Behind the MarketsWill this $2 AI stock double overnight?It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!Click here to learn more >>> About Cerecor Stock (NASDAQ:CERC)Cerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.Read More Ad Behind the MarketsWill this $2 AI stock double overnight?It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!Click here to learn more >>> CERC Stock News HeadlinesDecember 19, 2023 | benzinga.comAytu BioPharma Stock (NASDAQ:AYTU) Insider TradesAugust 24, 2023 | uk.finance.yahoo.commTOR Inhibitors Global Market Report 2023April 25, 2024 | American Alternative (Ad)Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st This guide shows you what to do next. In a cashless society, Biden forces you to use the government's new "digital dollar"...May 11, 2023 | finance.yahoo.comDelveInsight Highlights Major Advances, Transformative Therapies, and 80+ Leading Players Wheeling the Crohn's Disease Pipeline LandscapeSeptember 28, 2022 | finance.yahoo.comEdited Transcript of AYTU.OQ earnings conference call or presentation 27-Sep-22 8:30pm GMT - Yahoo FinanceSeptember 28, 2022 | seekingalpha.comAytu BioPharma, Inc. (AYTU) CEO Josh Disbrow on Q4 2022 Results - Earnings Call Transcript - Seeking AlphaAugust 31, 2022 | marketwatch.comDiGeorge Syndrome Drug Market In-Depth Analysis Research Report 2029August 24, 2022 | streetinsider.comValenzaBio Appoints Industry Veteran Peter Greenleaf to its Board of Directors - StreetInsider.comApril 25, 2024 | American Alternative (Ad)Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st This guide shows you what to do next. In a cashless society, Biden forces you to use the government's new "digital dollar"...August 24, 2022 | businesswire.comValenzaBio Appoints Industry Veteran Peter Greenleaf to its Board of Directors - Business WireAugust 11, 2022 | globenewswire.comCelldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update - GlobeNewswireAugust 9, 2022 | streetinsider.comCelldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update - StreetInsider.comAugust 8, 2022 | marketscreener.comCelldex Therapeutics : Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Form 8-K - Marketscreener.comJuly 24, 2022 | seekingalpha.comAvalo Therapeutics, Inc. (AVTX) Stock Price Today, Quote & News - Seeking AlphaJuly 15, 2022 | bizjournals.comPhiladelphia biotech news: Updates from CHOP, Helius Medical, GSK and more - Philadelphia Business Journal - The Business JournalsMay 3, 2022 | prnewswire.comThe Axial Spondyloarthritis Market is Predicted to Grow with a CAGR of 4.7% by 2032, Analyzes DelveInsight - PR NewswireMay 1, 2022 | marketwatch.comDiGeorge Syndrome Drug Market Size, Share, Industry Growth & Forecast By 2029April 8, 2022 | marketscreener.comAACR Poster Presentation: CFT7455 Phase 1/2 Cohort A - Marketscreener.comMarch 28, 2022 | benzinga.comDiGeorge Syndrome Drug Market High Demand, Size, Share, Processing Industry, And Forecast By 2029 - Benzi - BenzingaNovember 10, 2021 | businesswire.comModel N Announces Fourth Quarter and Fiscal Year 2021 Financial Results - Business WireNovember 10, 2021 | nasdaq.comModel N (MODN) Q4 Earnings & Revenues Top Estimates, Up Y/Y - NasdaqNovember 9, 2021 | finance.yahoo.comModel N Announces Fourth Quarter and Fiscal Year 2021 Financial Results - Yahoo FinanceNovember 9, 2021 | finance.yahoo.comAvalo Reports Third Quarter 2021 Financial Results and Provides Business Updates - Yahoo FinanceNovember 9, 2021 | stockhouse.comModel N Announces Fourth Quarter and Fiscal Year 2021 Financial Results - StockhouseOctober 7, 2021 | finance.yahoo.comHorizon Technology Finance Provides Third Quarter 2021 Portfolio Update - Yahoo FinanceAugust 27, 2021 | bizjournals.comInovio's experimental Covid-19 vaccine takes another step, plus other life sciences news - Philadelphia Business Journal - Philadelphia Business JournalAugust 27, 2021 | marketscreener.comCERECOR : Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc (Form 8-K) - Marketscreener.comSee More Headlines Receive CERC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cerecor and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2021Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:CERC CUSIPN/A CIK1534120 Webwww.cerecor.com Phone(410) 522-8707FaxN/AEmployees31Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,500,000.00 Net Margins-1,194.82% Pretax MarginN/A Return on Equity-261.82% Return on Assets-133.96% Debt Debt-to-Equity Ratio0.79 Current Ratio2.19 Quick Ratio2.18 Sales & Book Value Annual Sales$6.70 million Price / Sales186.29 Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / Book59.09Miscellaneous Outstanding Shares96,009,000Free FloatN/AMarket Cap$1.25 billion OptionableNot Optionable Beta1.44 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMichael F. ColaChairman & Chief Executive OfficerSchond L. GreenwayChief Financial Officer & TreasurerH. Jeffrey WilkinsChief Medical OfficerGarry Arthur NeilChief Scientific OfficerYounok Dumortier ShinChief Technology OfficerKey CompetitorsKiniksa PharmaceuticalsNASDAQ:KNSAPacira BioSciencesNASDAQ:PCRXSpyre TherapeuticsNASDAQ:SYRELigand PharmaceuticalsNASDAQ:LGNDVerona PharmaNASDAQ:VRNAView All Competitors CERC Stock Analysis - Frequently Asked Questions How were Cerecor's earnings last quarter? Cerecor Inc. (NASDAQ:CERC) posted its quarterly earnings data on Sunday, August, 1st. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.01. The firm had revenue of $3.36 million for the quarter. Cerecor had a negative trailing twelve-month return on equity of 261.82% and a negative net margin of 1,194.82%. What other stocks do shareholders of Cerecor own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cerecor investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), KushCo (KSHB), Novan (NOVN), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI). This page (NASDAQ:CERC) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry Research1970’s computer coder issues shocking A.I. warningTradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerecor Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
